These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 39183351

  • 1. Predicting early appropriate therapy for patients infected by carbapenem-resistant Gram-negative pathogens in intensive care units in Italy.
    Bassetti M, Monti G, Henriksen AS, Longshaw C.
    Antimicrob Resist Infect Control; 2024 Aug 26; 13(1):91. PubMed ID: 39183351
    [Abstract] [Full Text] [Related]

  • 2. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ, Hellenic Cefiderocol Study Group.
    J Antimicrob Chemother; 2017 Jun 01; 72(6):1704-1708. PubMed ID: 28369471
    [Abstract] [Full Text] [Related]

  • 3. In vitro activity of cefiderocol against European Pseudomonas aeruginosa and Acinetobacter spp., including isolates resistant to meropenem and recent β-lactam/β-lactamase inhibitor combinations.
    Santerre Henriksen A, Jeannot K, Oliver A, Perry JD, Pletz MW, Stefani S, Morrissey I, Longshaw C, ARTEMIS Study Investigators.
    Microbiol Spectr; 2024 Apr 02; 12(4):e0383623. PubMed ID: 38483164
    [Abstract] [Full Text] [Related]

  • 4. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA.
    Drugs; 2019 Feb 02; 79(3):271-289. PubMed ID: 30712199
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
    Jia P, Zhu Y, Zhang H, Cheng B, Guo P, Xu Y, Yang Q.
    BMC Microbiol; 2022 Oct 01; 22(1):234. PubMed ID: 36182895
    [Abstract] [Full Text] [Related]

  • 6. In Vitro Activity of Cefiderocol against U.S. and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program.
    Shortridge D, Streit JM, Mendes R, Castanheira M.
    Microbiol Spectr; 2022 Apr 27; 10(2):e0271221. PubMed ID: 35262394
    [Abstract] [Full Text] [Related]

  • 7. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV, Briceno DF, Ruiz SJ, Furtado GH, Nicolau DP.
    Braz J Infect Dis; 2011 Apr 27; 15(5):413-9. PubMed ID: 22230846
    [Abstract] [Full Text] [Related]

  • 8. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C, Freire S, Nordmann P, Poirel L.
    Eur J Clin Microbiol Infect Dis; 2024 Feb 27; 43(2):339-354. PubMed ID: 38095831
    [Abstract] [Full Text] [Related]

  • 9. In vitro activity of cefiderocol against carbapenemase-producing and meropenem-non-susceptible Gram-negative bacteria collected in the Japan Antimicrobial Resistant Bacterial Surveillance.
    Kayama S, Kawakami S, Kondo K, Kitamura N, Yu L, Hayashi W, Yahara K, Sugawara Y, Sugai M.
    J Glob Antimicrob Resist; 2024 Sep 27; 38():12-20. PubMed ID: 38789082
    [Abstract] [Full Text] [Related]

  • 10. Treatment of infections caused by multidrug-resistant Gram-negative bacilli: A practical approach by the Italian (SIMIT) and French (SPILF) Societies of Infectious Diseases.
    Meschiari M, Asquier-Khati A, Tiseo G, Luque-Paz D, Murri R, Boutoille D, Falcone M, Mussini C, Tattevin P, Italian Society of Infectious and Tropical Diseases (SIMIT), and the French Society of Infectious Diseases (SPILF).
    Int J Antimicrob Agents; 2024 Jul 27; 64(1):107186. PubMed ID: 38688353
    [Abstract] [Full Text] [Related]

  • 11. Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Jean SS, Lee WS, Yu KW, Liao CH, Hsu CW, Chang FY, Ko WC, Chen RJ, Wu JJ, Chen YH, Chen YS, Liu JW, Lu MC, Lam C, Liu CY, Hsueh PR.
    J Microbiol Immunol Infect; 2016 Dec 27; 49(6):969-976. PubMed ID: 25661253
    [Abstract] [Full Text] [Related]

  • 12. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan.
    Hsueh SC, Lee YJ, Huang YT, Liao CH, Tsuji M, Hsueh PR.
    J Antimicrob Chemother; 2019 Feb 01; 74(2):380-386. PubMed ID: 30357343
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P, Hasçelik G, Unal S.
    Mikrobiyol Bul; 2006 Jul 01; 40(3):147-54. PubMed ID: 17001842
    [Abstract] [Full Text] [Related]

  • 17. [Surveillance of resistance in the intensive care units using a cumulative antibiogram].
    Yürüyen C, Daldaban Dinçer Ş, Yanılmaz Ö, Boz ES, Aksaray S.
    Mikrobiyol Bul; 2018 Oct 01; 52(4):329-339. PubMed ID: 30522419
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec 01; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.